alpha-Galactosidase A deficient mice: a model of Fabry disease.
Fabry disease is an X-linked inherited metabolic disorder that is caused by a deficiency of alpha-galactosidase A (alpha-Gal A). Progressive deposition of neutral glycosphingolipids that have terminal a-linked galactosyl moieties in vascular endothelial cells causes renal failure along with premature myocardial infarctions and strokes in patients with this condition. No specific treatment is available for patients with this disorder at this time. An animal model of this condition would be valuable for exploring therapeutic strategies for patients with Fabry disease. We report here the generation of alpha-Gal A deficient mice by gene targeting and an analysis of the resulting phenotype. The knockout mice display a complete lack of alpha-Gal A activity. The mice, however, appeared clinically normal at 10 weeks of age. Ultrastructural analysis revealed concentric lamellar inclusions in the kidneys, and confocal microscopy using a fluorescent-labeled lectin specific for alpha-D-galactosyl residues showed accumulation of substrate in the kidneys as well as in cultured fibroblasts. Lipid analysis revealed a marked accumulation of ceramidetrihexoside in the liver and the kidneys. These findings indicate the similarity of the pathophysiological process in the mutant mice and in patients with Fabry disease. The deficiency of alpha-Gal A activity and the accumulation of material containing terminal alpha-galactosyl residues in cultured embryonic fibroblasts derived from alpha-Gal A(-/0) mice were corrected by transducing these cells with bicistronic multidrug resistance retroviruses containing human alpha-Gal A cDNA.
Ohshima
T
T
Gene Targeting Research and Core Facility, National Institute of Dental Research, National Institutes of Health, Bethesda, MD 20892, USA.
Murray
G J
GJ
Swaim
W D
WD
Longenecker
G
G
Quirk
J M
JM
Cardarelli
C O
CO
Sugimoto
Y
Y
Pastan
I
I
Gottesman
M M
MM
Brady
R O
RO
Kulkarni
A B
AB
D000818:Animals; D002678:Chimera; D003433:Crosses, Genetic; D004195:Disease Models, Animal; D000795:Fabry Disease / Q000201:enzymology* / Q000235:genetics / Q000628:therapy; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D007668:Kidney / Q000201:enzymology* / Q000473:pathology / Q000648:ultrastructure; D037102:Lectins; D008099:Liver / Q000201:enzymology / Q000473:pathology; D008247:Lysosomes / Q000201:enzymology / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008854:Microscopy, Electron; D037121:Plant Lectins; D000519:alpha-Galactosidase / Q000096:biosynthesis / Q000235:genetics
C045475:Griffonia simplicifolia lectins; D037102:Lectins; D037121:Plant Lectins; D000519:alpha-Galactosidase